CA2765602C - N-terminal truncated protofibrils/oligomers for use in therapeutic and diagnostic methods for alzheimer's disease and related disorders - Google Patents

N-terminal truncated protofibrils/oligomers for use in therapeutic and diagnostic methods for alzheimer's disease and related disorders Download PDF

Info

Publication number
CA2765602C
CA2765602C CA2765602A CA2765602A CA2765602C CA 2765602 C CA2765602 C CA 2765602C CA 2765602 A CA2765602 A CA 2765602A CA 2765602 A CA2765602 A CA 2765602A CA 2765602 C CA2765602 C CA 2765602C
Authority
CA
Canada
Prior art keywords
antibody
protofibril
terminal truncated
alzheimer
protofibrils
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2765602A
Other languages
English (en)
French (fr)
Other versions
CA2765602A1 (en
Inventor
Paer Gellerfors
Lars Lannfelt
Linda Soederberg
Karin Tegerstedt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioarctic AB
Original Assignee
Bioarctic AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioarctic AB filed Critical Bioarctic AB
Publication of CA2765602A1 publication Critical patent/CA2765602A1/en
Application granted granted Critical
Publication of CA2765602C publication Critical patent/CA2765602C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2765602A 2009-06-29 2010-06-29 N-terminal truncated protofibrils/oligomers for use in therapeutic and diagnostic methods for alzheimer's disease and related disorders Active CA2765602C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22110509P 2009-06-29 2009-06-29
US61/221,105 2009-06-29
PCT/IB2010/052947 WO2011001366A1 (en) 2009-06-29 2010-06-29 N-terminal truncated amyloid beta protofibrils/ oligomers for use in therapeutic and diagnostic methods for alzheimer's disease

Publications (2)

Publication Number Publication Date
CA2765602A1 CA2765602A1 (en) 2011-01-06
CA2765602C true CA2765602C (en) 2021-05-25

Family

ID=42832352

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2765602A Active CA2765602C (en) 2009-06-29 2010-06-29 N-terminal truncated protofibrils/oligomers for use in therapeutic and diagnostic methods for alzheimer's disease and related disorders

Country Status (16)

Country Link
US (2) US20120100129A1 (enExample)
EP (2) EP2448968B1 (enExample)
JP (3) JP2012532094A (enExample)
AU (1) AU2010267640B2 (enExample)
CA (1) CA2765602C (enExample)
CY (1) CY1124034T1 (enExample)
DK (1) DK2448968T3 (enExample)
ES (1) ES2864049T3 (enExample)
HR (1) HRP20210611T1 (enExample)
HU (1) HUE053949T2 (enExample)
LT (1) LT2448968T (enExample)
PL (1) PL2448968T3 (enExample)
PT (1) PT2448968T (enExample)
SI (1) SI2448968T1 (enExample)
SM (1) SMT202100237T1 (enExample)
WO (1) WO2011001366A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
BRPI0709050B1 (pt) 2006-03-23 2018-12-26 Bioarctic Neuroscience Ab anticorpo ou fragmento do mesmo, composição, métodos para detectar protofibrilas ab in vitro, e, uso do anticorpo
EP2539366B1 (en) 2010-02-26 2017-11-08 BioArtic Neuroscience AB Protofibril-binding antibodies and their use in therapeutic and diagnostic methods for parkinson's disease, dementia with lewy bodies and other alpha-synucleinopathies
CN103459421B (zh) * 2011-03-16 2017-07-14 前体生物药物股份公司 诊断性抗体测定
HRP20210680T1 (hr) 2014-07-10 2021-06-11 Bioarctic Ab POBOLJŠANA PROTUTIJELA KOJA VEŽU Aβ PROTOFIBRIL
CN107849125A (zh) 2015-07-21 2018-03-27 生命北极神经科学公司 用于治疗靶向聚集的肽的创伤性脑损伤的方法
CA3028035A1 (en) 2016-07-14 2018-01-18 Bioarctic Ab Brain delivery protein
EP3658172A4 (en) 2017-07-25 2021-05-05 TrueBinding, Inc. TREATING CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND HIS LIGAND
CA3107370A1 (en) 2018-07-24 2020-01-30 Eisai R&D Management Co., Ltd. Methods of treatment and prevention of alzheimer's disease
CN113711036B (zh) 2019-01-30 2025-03-18 真和制药有限公司 抗gal3抗体及其用途
JPWO2021006212A1 (enExample) * 2019-07-08 2021-01-14
WO2021055670A1 (en) 2019-09-20 2021-03-25 Avx Corporation Somatic cell-based electrical biosensor
CN116157151A (zh) 2020-05-26 2023-05-23 真和制药有限公司 通过阻断半乳凝素-3治疗炎性疾病的方法
HUE072262T2 (hu) 2020-06-26 2025-11-28 Bioarctic Ab Alfa-szinuklein protofibrillum-kötõ antitestek
AU2022307687A1 (en) 2021-07-09 2024-01-04 Eisai R&D Management Co., Ltd. Biomarkers for alzheimer's disease treatment
EP4395821A1 (en) 2021-08-30 2024-07-10 Eisai R&D Management Co., Ltd. Subcutaneous formulations of anti-abeta protofibril antibody and methods of use thereof
JP2025506389A (ja) 2022-02-02 2025-03-11 エーザイ・アール・アンド・ディー・マネジメント株式会社 ｐ－タウ１８１レベルを使用した治療方法
EP4638494A1 (en) 2022-12-22 2025-10-29 BioArctic AB Antibody which binds to abetape3
TW202607032A (zh) 2024-06-20 2026-02-16 瑞典商生物極公司 雙特異性結合分子

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5604102A (en) 1992-04-15 1997-02-18 Athena Neurosciences, Inc. Methods of screening for β-amyloid peptide production inhibitors
EP1571158B1 (en) * 1999-08-04 2009-10-14 University Of Southern California Globular assembly of amyloid beta protein and uses thereof
EP2082749A3 (en) 2000-07-07 2010-06-30 Bioarctic Neuroscience AB Prevention and treatment of Alzheimer's disease
US7122374B1 (en) * 2002-04-09 2006-10-17 Takaomi Saido Amyloid beta-protein 3(pE)-42 antibodies and uses thereof
EP1523499A2 (en) * 2002-07-24 2005-04-20 Innogenetics N.V. Fragments of beta-amyloid as targets for vaccination against alzheimer disease
PT1737891E (pt) * 2004-04-13 2013-04-16 Hoffmann La Roche Anticorpos anti p-selectina
GB0413726D0 (en) * 2004-06-18 2004-07-21 Lauras As Compounds
SE0401601D0 (sv) * 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
GEP20115195B (en) * 2004-07-30 2011-04-11 Rinat Neuroscience Corp Antibodies directed against amyloid-beta peptide and use thereof
BRPI0709050B1 (pt) * 2006-03-23 2018-12-26 Bioarctic Neuroscience Ab anticorpo ou fragmento do mesmo, composição, métodos para detectar protofibrilas ab in vitro, e, uso do anticorpo
EP2207568B1 (en) * 2007-11-16 2017-05-31 The Rockefeller University Antibodies specific for the protofibril form of beta-amyloid protein
DK2282758T3 (en) * 2008-04-29 2019-02-25 Bioarctic Ab ANTIBODIES AND VACCINES FOR USE IN THERAPEUTIC AND DIAGNOSTIC PROCEDURES FOR ALPHA-SYNUCLEIN-RELATED DISORDERS

Also Published As

Publication number Publication date
AU2010267640A1 (en) 2012-01-19
CY1124034T1 (el) 2022-05-27
SMT202100237T1 (it) 2021-05-07
SI2448968T1 (sl) 2021-07-30
HUE053949T2 (hu) 2021-08-30
JP2012532094A (ja) 2012-12-13
JP2019218362A (ja) 2019-12-26
EP2448968A1 (en) 2012-05-09
JP6884025B2 (ja) 2021-06-09
LT2448968T (lt) 2021-05-10
PL2448968T3 (pl) 2021-09-13
HRP20210611T1 (hr) 2021-05-28
PT2448968T (pt) 2021-04-30
CA2765602A1 (en) 2011-01-06
EP3892633A1 (en) 2021-10-13
WO2011001366A1 (en) 2011-01-06
AU2010267640B2 (en) 2015-03-05
US20230295283A1 (en) 2023-09-21
ES2864049T3 (es) 2021-10-13
US20120100129A1 (en) 2012-04-26
DK2448968T3 (da) 2021-04-12
EP2448968B1 (en) 2021-01-27
JP2017197531A (ja) 2017-11-02

Similar Documents

Publication Publication Date Title
US20230295283A1 (en) N-terminal truncated protofibrils/ oligomers for use in therapeutic and diagnostic methods for alzheimer's
KR101591206B1 (ko) 치료적 특성을 갖는 베타 1-42 특이적인 단일클론성 항체
US20200215209A1 (en) Antibodies and Vaccines for Use in Therapeutic and Diagnostic Methods for Alpha-Synuclein-Related Disorders
KR101600095B1 (ko) 모노클로널 항 베타 아밀로이드 항체
CN101883790B (zh) 抗淀粉样蛋白β抗体在眼病中的用途
JP6128535B2 (ja) 抗体及びその利用
JP7204235B2 (ja) 活性型α－シヌクレインに結合する抗体
KR101713365B1 (ko) 안전하고 기능적인 인간화 항 베타-아밀로이드 항체
CN101325972B (zh) 具有治疗性质的Aβ1-42特异性单克隆抗体
JP2022528459A (ja) 融合構築物及びその使用
HK40057935A (en) Antibodies selective for n-terminaltruncated amyloid-p protofibrils/oligomers
HK40007334A (en) Antibodies and vaccines for use in therapeutic and diagnostic methods for alpha-synucleinrelated disorders
HK1124532B (zh) 具有治疗性质的Aβ1-42特异性单克隆抗体

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20150501

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 15TH ANNIV.) - STANDARD

Year of fee payment: 15

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250506

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250506

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 16TH ANNIV.) - STANDARD

Year of fee payment: 16

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260505

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260505